
    
      Patients included in the study will receive a 6 week cycle consisting of Bendamustine
      administered IV at doses of 90 mg/m2 on days 1 and 4 of the first cycle and days 1 and 8 in
      subsequent cycles in combination with Bortezomib as a bolus dose of 1.3 mg/m2 on days 1, 4,
      8, 11, 22, 25, 29 and 32, and oral prednisone at doses of 60 mg/m2, during the first four
      days of each cycle.

      Then, patients will receive eight additional cycles of 5-week . The same pattern consisting
      of bendamustine and prednisone but bortezomib is administered as an intravenous bolus dose of
      1.3 mg/m2 on days 1, 8, 15 and 22.
    
  